Currently, HHT is the only ribosome inhibitor specifically used for the treatment of acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS)5. Here, ACVRL1 is linked to myelodysplastic syndrome.